Drugs / 5F11-Ts
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03049449 | Mar 2017 → Jan 2022 | anaplastic large cell lymphoma, diffuse large B-cell lymphoma, enteropathy-associated T-cell lymphoma, extranodal nasal NK/T cell lymphoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5F11-Ts | “Safety and feasibility of 5F11-28Z-transduced T cells (5F11-Ts) were evaluated in a phase 1 dose escalation clinical trial.” PMID 37939262 ↗ Feb 2024 |
| Action | Deplete | “We have constructed a novel fully-human anti-CD30 CAR that can specifically recognize CD30-expressing target cells in vitro and eradicate CD30-expressing tumors in mice.” NCT03049449 ↗ |
| Modality | Cell therapy | “T cells obtained by leukapheresis will be genetically modified to express an anti-CD30 CAR.” NCT03049449 ↗ |
| Route | Other | “infusion of 5F11-Ts on day 0” PMID 37939262 ↗ Feb 2024 |